secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-045527
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru Q1 net loss narrows to $5.3M; cash $33M; Phase 2b obesity trial on track
-----------------------------------------------------------------------------

- Net loss of $5.3M ($0.26 per share) vs $8.9M ($0.61) in Q1 FY2025.
- Cash, cash equivalents and restricted cash increased to $33.0M from $15.8M at Sep 30, 2025.
- Operating loss from continuing operations improved to $5.4M from $10.2M.
- Phase 2b PLATEAU trial of enobosarm+semaglutide in obesity to start Q1 2026; interim analysis Q1 2027.
- R&D spend fell to $1.3M from $5.7M; G&A to $4.1M from $5.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/0001193125-26-045527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-045527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer